Expect BIIB to be a bidder in this process to buy ONYX. if they get them or ( CLVS ,PCYC) then we will see a big pop in BIBI prices.Management knows how to execute all they need is new drug candidates
Sentiment: Strong Buy
Will not happen. BIIB sold off all of their Rheumatology and Oncology interests back in 2010 to focus on Neurology and Hemophilia.
I agree with veno, onyx is outside of BIIB's area of focus and they currently have a number of potential treatments in their own pipeline.